Delivery Order SPE2DB24D8002-SPE2DB24FJMSW
Award Date
8/8/24
Potential Completion Date
8/9/24
Potential Value
$4.2K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $5,339.83 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has an ultimate completion date of July 24, 2024 and is part of the DLA Troop Support Medical's ECAT Generation V Program, which procures commercial medical equipment, accessories, consumables, and medical simulation equipment. Dakota Drug,...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $2,673.87 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4567655331 DUPIXENT 300 MG/2 ML PEN 2ML. This contract has an ultimate completion date of March 24, 2025 and was awarded on March 21, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the procurement of DUPIXENT 300 MG/2 ML PEN 2ML medical supplies. The contract, valued at $13,423.69, has an ultimate completion date of March 7, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S....
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,644.03, is for the delivery of Dupixent 300 mg/2 ml pens, a pharmaceutical product. The contract has a firm fixed price pricing type and a performance period ending on June 5, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml pen 2 ml. The contract, identified as SPE2DB24D8001|SPE2DB25FKZRM, has a ceiling value of $5,554.54 and a period of performance through May 8, 2025. This order is part of DLA Troop Support Medical's ECAT Generation V Program, a larger indefinite delivery contract with Dakota Drug, Inc. valued at...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The $5,601.75 contract is for the supply of Dupixent 300 mg/2 ml syringes, with a performance period through August 1, 2024. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows...
The U.S. government's Defense Logistics Agency (DLA) awarded a $26,588.72 firm-fixed-price delivery order contract (SPE2DX15D8003|SPE2DX24F7D7B) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml syringes. The contract has a performance period through May 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (SPE2DB24D8001) as part of the DLA's ECAT...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $6,356.82. The contract is a delivery order with a firm fixed price and an ultimate completion date of March 12, 2025. The contract is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with...
The Defense Logistics Agency (DLA) awarded a $8,232.42 firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of DUPIXENT 300 MG/2 ML SYRINGE 2ML. This order was placed under Dakota Drug's $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, which supports the agency's ECAT Generation V Program for procuring commercial medical equipment, accessories, consumables, and simulation equipment. The contract has an...